



PRESS RELEASE

CHANGE IN SHARE CAPITAL

UPDATED BY-LAWS FILED

Capua, 17 June 2016 - **Pierrel S.p.A.** (the "**Company**") announces that, following the reduction of the share capital of € 11,548,506.75 approved by the Shareholders Meeting on 30 May last as a measure taken in the context of the requirements pursuant to Article 2446 of the Civil Code, the new composition of the share capital (completely subscribed and paid up), deposited today, is represented in the following table.

	Current share capital			Previous share capital		
	<i>Euro</i>	<i>Share no.</i>	<i>Unit per value</i>	<i>Euro</i>	<i>Share no.</i>	<i>Unit per value</i>
Total of which:	50,000.00	54,293,573	Ordinary shares with nominal value of zero	11,598,506.75	54,293,573	Ordinary shares with nominal value of zero
Ordinary shares with regular dividend rights from 1 January 2016	50,000.00	54,293,573	Ordinary shares with nominal value of zero	11,598,506.75	54,293,573	Ordinary shares with nominal value of zero
Outstanding coupon 05						

The company also announces that the new by-laws, filed today, is available to the public at the registered office of the Company in in Capua, at S.S. Appia 7-bis 46/48, on the website of the Company www.pierrelgroup.com, section *Investor Relations / Corporate Governance / Documents and Reports*, and at the central storage mechanism Nis-Storage, authorised by Consob and available at www.emarketstorage.com.

* * *

Pierrel S.p.A. is a global supplier to the pharmaceutical industry, specialising in the pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics.

Pierrel has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines.

The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.

Investor Relations

Raffaele Petrone

Global Consult s.r.l.

Media Relations

Rossana Del Forno



E-mail: investor.relations@pierrelgroup.com
tel. +39 0823 626 111
fax +39 0823 626 228

E-mail: areacomunicazione@globalconsultsrl.com
tel. +39 333 6178665